BDTX: Black Diamond Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for BDTX
Across the 10 sessions after earlier BDTX headlines, the stock closed higher 4 times and lower 6 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BDTX | SPY |
|---|---|---|---|
| May 22, 2026 | Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | -35.8% | +0.4% |
| May 19, 2026 | Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC | +16.3% | -0.7% |
| May 7, 2026 | Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | -3.5% | -0.3% |
| Apr 21, 2026 | Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting | +3.3% | -0.7% |
| Mar 17, 2026 | Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | +1.8% | +0.3% |
| Mar 3, 2026 | Black Diamond Therapeutics to Participate in Upcoming Investor Conferences | -5.3% | -0.9% |
Quantisnow market dataNASDAQ
BDTX
Black Diamond Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for BDTX
Full BDTX profile on Quantisnow Follow BDTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time